Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GOT1 | P17174 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30421162 | 0.91 | CYP1A2 (0.51) | CYP1A2P2RX7CTDSP1CES1VNN1 | |
| SCHEMBL10772468 | 0.91 | CYP1A2 (0.51) | CYP1A2P2RX7CTDSP1CES1VNN1 | |
| SCHEMBL6046250 | 0.86 | CYP1A2 (0.50) | CYP1A2CTDSP1CYP2C19SMN1; SMN2CES1 | |
| SCHEMBL27449978 | 0.81 | TBXAS1 (0.53) | CYP1A2CTDSP1SMN1; SMN2CES1TBXAS1 | |
| SCHEMBL18854185 | 0.80 | CYP1A2 (0.44) | CYP1A2P2RX7CTDSP1CYP2C19SMN1; SMN2 | |
| SCHEMBL27883898 | 0.79 | CYP1A2 (0.50) | CYP1A2P2RX7CTDSP1CYP2C19SMN1; SMN2 | |
| SCHEMBL30421462 | 0.79 | CYP1A2 (0.54) | CYP1A2P2RX7CTDSP1CES1VNN1 | |
| SCHEMBL31187687 | 0.79 | CES1 (0.49) | CYP1A2P2RX7CTDSP1CYP2C19SMN1; SMN2 | |
| SCHEMBL9842898 | 0.79 | TBXAS1 (0.54) | CYP1A2CES1TBXAS1TBXA2R | |
| SCHEMBL31080880 | 0.78 | CYP1A2 (0.53) | CYP1A2P2RX7CTDSP1CES1VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | CYP1A2 414/4885P2RX7 2167/4885CTDSP1 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.